We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+1.1%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$800M
AUM Growth
-$196M
(-20%)
Cap. Flow
-$191M
Cap. Flow
% of AUM
-23.93%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
76
New
18
Increased
11
Reduced
22
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$44.5M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$28.7M |
| 3 |
Agilent Technologies
A
|
+$25.7M |
| 4 |
Amgen
AMGN
|
+$18.3M |
| 5 |
DexCom
DXCM
|
+$15.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$73M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$47.1M |
| 3 |
Natera
NTRA
|
+$39.7M |
| 4 |
Boston Scientific
BSX
|
+$34.1M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$27.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.7B
| $64.3M | 8.05% |
759,038
+18,090
| +2% | +$1.61M |
|
|
2
AbbVie
ABBV
$455B
| $41.6M | 5.21% |
+310,250
| New | +$44.5M |
|
|
3
Agilent Technologies
A
$39.2B
| $41.1M | 5.14% |
338,030
+199,750
| +144% | +$25.7M |
|
|
4
Boston Scientific
BSX
$68.4B
| $37.1M | 4.64% |
958,600
-849,390
| -47% | -$34.1M |
|
5
Eli Lilly
LLY
$1.03T
| $33.4M | 4.17% |
103,150
+32,520
| +46% | +$10.3M |
|
6
Cencora
COR
$60.7B
| $32.4M | 4.05% |
239,150
+82,240
| +52% | +$11.8M |
|
7
UnitedHealth
UNH
$383B
| $31.8M | 3.98% |
62,980
-5,250
| -8% | -$2.76M |
|
8
Danaher
DHR
$138B
| $30.4M | 3.81% |
132,878
+23,597
| +22% | +$5.78M |
|
9
Tenet Healthcare
THC
$20.3B
| $26.8M | 3.35% |
518,990
| – | – |
|
|
10
Thermo Fisher Scientific
TMO
$214B
| $26M | 3.25% |
+51,240
| New | +$28.7M |
|
11
Centene
CNC
$30.1B
| $23.4M | 2.93% |
300,970
-239,890
| -44% | -$21.4M |
|
12
Cigna
CI
$76.1B
| $21.3M | 2.67% |
76,910
-19,560
| -20% | -$5.5M |
|
13
Cytokinetics
CYTK
$10.9B
| $21.1M | 2.63% |
434,560
-51,040
| -11% | -$2.46M |
|
14
Humana
HUM
$44B
| $20.8M | 2.6% |
42,920
-4,300
| -9% | -$2.09M |
|
15
Syndax Pharmaceuticals
SNDX
$1.73B
| $20.6M | 2.58% |
859,240
-64,160
| -7% | -$1.44M |
|
|
16
DexCom
DXCM
$28.8B
| $20.4M | 2.55% |
253,500
+178,720
| +239% | +$15.1M |
|
|
17
Biogen
BIIB
$30.7B
| $18.7M | 2.34% |
69,950
-343,690
| -83% | -$73M |
|
18
Elevance Health
ELV
$81.6B
| $17.7M | 2.21% |
38,910
-15,320
| -28% | -$7.33M |
|
|
19
Amgen
AMGN
$209B
| $17M | 2.12% |
+75,370
| New | +$18.3M |
|
20
LivaNova
LIVN
$4.45B
| $16.7M | 2.08% |
328,030
-158,520
| -33% | -$9.41M |
|
21
Henry Schein
HSIC
$9.7B
| $16.4M | 2.05% |
248,920
| – | – |
|
22
Bristol-Myers Squibb
BMY
$132B
| $15.9M | 1.98% |
223,150
-189,270
| -46% | -$13.7M |
|
23
Incyte
INCY
$24.9B
| $15.2M | 1.9% |
227,851
-6,279
| -3% | -$464K |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.2M | 1.78% |
229,530
-674,320
| -75% | -$47.1M |
|
25
Becton Dickinson
BDX
$45.6B
| $14M | 1.75% |
62,930
+7,220
| +13% | +$1.8M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2022 Portfolio in Review
As of Q3 2022, HealthCor Management held 76 positions worth $800M, down 20% from $995M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
HealthCor Management withdrew a net $191M in Q3 2022, closing 17 positions and reducing 22 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Financials.
Against the trend, HealthCor Management opened a new position in AbbVie worth $41.6M.
- HealthCor Management's largest Q3 2022 buy was AbbVie: 310,250 shares worth $41.6M.
- HealthCor Management added most to Agilent Technologies in Q3 2022, an estimated $25.7M increase.
- HealthCor Management's biggest Q3 2022 reduction was Biogen, cutting an estimated $73M.
- HealthCor Management fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $27.2M.
- HealthCor Management's ten largest holdings make up 46% of its $800M portfolio in Q3 2022.
- HealthCor Management opened 18 new positions and closed 17 in Q3 2022.
- HealthCor Management's portfolio value fell 20% quarter-over-quarter to $800M.
Based on HealthCor Management's 13F filing for Q3 2022, filed 14 Nov 2022.